BRPI0913778A2 - "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico" - Google Patents

"métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"

Info

Publication number
BRPI0913778A2
BRPI0913778A2 BRPI0913778A BRPI0913778A BRPI0913778A2 BR PI0913778 A2 BRPI0913778 A2 BR PI0913778A2 BR PI0913778 A BRPI0913778 A BR PI0913778A BR PI0913778 A BRPI0913778 A BR PI0913778A BR PI0913778 A2 BRPI0913778 A2 BR PI0913778A2
Authority
BR
Brazil
Prior art keywords
methods
lupus
prognosis
diagnosis
diagnosing
Prior art date
Application number
BRPI0913778A
Other languages
English (en)
Portuguese (pt)
Inventor
Geoffrey Hom
Robert R Graham
Timothy W Behrens
Ward A Ortmann
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0913778A2 publication Critical patent/BRPI0913778A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0913778A 2008-09-26 2009-09-25 "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico" BRPI0913778A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10065908P 2008-09-26 2008-09-26
PCT/US2009/058478 WO2010036960A2 (en) 2008-09-26 2009-09-25 Methods for treating, diagnosing, and monitoring lupus

Publications (1)

Publication Number Publication Date
BRPI0913778A2 true BRPI0913778A2 (pt) 2015-10-20

Family

ID=42060417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913778A BRPI0913778A2 (pt) 2008-09-26 2009-09-25 "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"

Country Status (11)

Country Link
US (1) US20100099101A1 (enExample)
EP (1) EP2344674A4 (enExample)
JP (1) JP2012503985A (enExample)
KR (1) KR20110081161A (enExample)
CN (1) CN102224258A (enExample)
AU (1) AU2009296393A1 (enExample)
BR (1) BRPI0913778A2 (enExample)
CA (1) CA2736373A1 (enExample)
IL (1) IL211462A0 (enExample)
MX (1) MX2011003273A (enExample)
WO (1) WO2010036960A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144761A2 (en) * 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
US20130034544A1 (en) 2009-10-07 2013-02-07 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
CN102465170A (zh) * 2010-11-05 2012-05-23 复旦大学附属华山医院 一种检测bank1基因单核苷酸多态性的方法
WO2012109427A1 (en) * 2011-02-10 2012-08-16 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
PE20141172A1 (es) * 2011-04-29 2014-09-22 Univ Washington Composiciones de nucleasa terapeuticas y metodos
CN102360016A (zh) * 2011-07-21 2012-02-22 南京工业大学 流式微球法对SLE的Sm-RNP抗体检测试剂盒的制备
MX2015004145A (es) * 2012-10-08 2015-07-06 Hoffmann La Roche Peptidos de penetracion celular que se unen a factor regulador de interferon 5.
WO2014058254A1 (ko) * 2012-10-10 2014-04-17 가톨릭대학교 산학협력단 １ｑ２５．１(RABGAP1L) 위치, 6P21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물
KR101491214B1 (ko) * 2012-10-10 2015-02-06 가톨릭대학교 산학협력단 １ｑ２５．１(RABGAP1L) 위치, 6p21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물
CN105051210B (zh) * 2013-02-08 2020-07-28 阿勒格尼-辛格研究所 细胞结合的补体激活产物作为狼疮前期的诊断性生物标志物
US20140278133A1 (en) * 2013-03-15 2014-09-18 Advanced Throughput, Inc. Systems and methods for disease associated human genomic variant analysis and reporting
CN103397103B (zh) * 2013-08-26 2016-04-20 中国人民解放军第三军医大学第三附属医院 一种检测socs家族基因标签单核甘酸多态性位点的方法及试剂盒
WO2015066550A1 (en) 2013-10-31 2015-05-07 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
EP2886140A1 (en) 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
WO2015175424A1 (en) * 2014-05-12 2015-11-19 Biogen Ma Inc. Biomarkers predictive of lupus progression and uses thereof
CN109790526A (zh) 2016-07-01 2019-05-21 分解治疗有限责任公司 优化的二核酸酶融合体和方法
KR102777015B1 (ko) 2017-08-22 2025-03-10 사나바이오, 엘엘씨 가용성 인터페론 수용체 및 그의 용도
JP2024536558A (ja) * 2021-10-18 2024-10-04 カーステン マニュファクチュアリング コーポレーション ゴルフクラブセンサハウジング

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2008144761A2 (en) * 2007-05-21 2008-11-27 Genentech, Inc. Methods and compositions for identifying and treating lupus
CA2749869A1 (en) * 2009-03-03 2010-09-10 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility

Also Published As

Publication number Publication date
US20100099101A1 (en) 2010-04-22
CA2736373A1 (en) 2010-04-01
EP2344674A4 (en) 2012-11-07
WO2010036960A8 (en) 2011-04-28
AU2009296393A1 (en) 2010-04-01
JP2012503985A (ja) 2012-02-16
KR20110081161A (ko) 2011-07-13
IL211462A0 (en) 2011-05-31
MX2011003273A (es) 2011-04-28
WO2010036960A3 (en) 2010-09-30
CN102224258A (zh) 2011-10-19
EP2344674A2 (en) 2011-07-20
WO2010036960A2 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0913778A2 (pt) "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"
GB201021399D0 (en) Oligonucleotide probe set and methods of microbiota profiling
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
BR112013006764A2 (pt) método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente
WO2008138578A3 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A8 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
BR112012031389A2 (pt) método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue
FR2943554B1 (fr) Systeme et procede d'observation d'une activite de nage d'une personne
WO2012054555A3 (en) Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
JP2012529655A5 (enExample)
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
BRPI0720116B8 (pt) método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2012018535A3 (en) Wellness panel
WO2005020784A3 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
BRPI1010069A2 (pt) "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2008141148A3 (en) Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease
WO2015034886A3 (en) Wellness panel for companion animals
Sabbagh et al. Alzheimer's disease biomarkers: correspondence between human studies and animal models
JP2009225428A5 (enExample)
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
Mishra et al. At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia
BR112013009592A2 (pt) método para avaliar e prever um efeito de um candidato a um agente terapêutico para tratar doença de alzheimer ou deficiência cognitiva moderada; método para diagnosticar e auxiliar o diagnóstico de doença de alzheimer ou deficiência cognitiva moderada; e método para seleção de um paciente que provavelmente se beneficiará com unm efeito terapêutico de um candidato a um agente terapêutico para tratar doença de alzheimer ou deficiência cognitiva moderada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.